Cell Therapy News

Results of early clinical trials suggest that chimeric antigen receptor T cells can be adapted successfully to target brain tumors, according to a presenter at AACR Virtual Special Conference: Brain Cancer.

The Society for Immunotherapy of Cancer will honor several recipients with its annual awards, presented this week during its 36th Annual Meeting & Pre-Conference Programs.

Chimeric antigen receptor T-cell therapy has induced exceptional response rates among patients with relapsed or refractory multiple myeloma compared with conventional options, according to a speaker at Chemotherapy Foundation Symposium.

COVID-19 remains a significant global burden, with 5 million worldwide deaths recorded as of October, according to a speaker at Chemotherapy Foundation Symposium.

Significant progress has been made in treatment and improving survival outcomes across all subtypes of acute lymphoblastic leukemia, according to a speaker at Chemotherapy Foundation Symposium.

Chimeric antigen receptor T-cell therapy appeared associated with various cardiovascular and pulmonary adverse events, according to results of a retrospective pharmacovigilance study.

Chimeric antigen receptor T-cell therapy followed by pembrolizumab appeared safe and feasible for patients with malignant pleural mesothelioma, phase 1 trial results published in Cancer Discovery showed.

The FDA has delayed its decision on a biologics license application for ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma.

The Society for Immunotherapy of Cancer announced the inaugural class of Fellows of the Academy of Immuno-Oncology.

The National Academy of Medicine announced the election of 90 regular members and 10 international members.